Analysis of Biomarkers and Marginal Bone Loss in Platform-Switched and Nonplatform-Switched Implants: A Randomized Clinical Trial.

ABSTRACT:

Objectives

To compare the peri-implant crevicular fluid (PICF) biomarker levels, peri-implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform-switched (NPS) or platform-switched (PS) abutments.

Methods

Ninety-four implants in 27 subjects were included in this study. Receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1) levels in PICF, peri-implant health, and the change in the MBL were evaluated at the time of restoration (T ₁) and after 12 months (T ₂).

Results

The IL-1β levels decreased and the RANKL, OPG, and MCP-1 levels increased from T ₁ to

SUBMITTER: Kocak-Oztug NA 

PROVIDER: S-EPMC9148225 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature